HCC1954-luc Orthotopic Mouse Model Service for Breast Cancer

The HCC1954-luc orthotopic mouse model offers a clinically relevant preclinical system for evaluating HER2-targeted therapies, combination regimens, and resistance mechanisms in an anatomically faithful human breast cancer setting. Alfa Cytology engineers and validates HCC1954-luc orthotopic xenografts with meticulous attention to cell line authentication, surgical precision, and longitudinal bioluminescence readouts—providing you with a robust platform to advance your preclinical HER2-positive breast cancer drug development pipeline.

Overview of HCC1954-luc Orthotopic Mouse Model for Breast Cancer

HCC1954 is a human breast cancer cell line originally established from a stage IIA, grade 3 invasive ductal carcinoma resected from a 61-year-old patient. Genetically, this line is characterized by amplification and overexpression of human epidermal growth factor receptor 2 (HER2/ErbB2), coupled with inactivating mutations in TP53 and activating mutations in PIK3CA—molecular hallmarks that drive constitutive PI3K/AKT and MAPK/ERK signaling and confer an aggressive, rapidly proliferating phenotype. The HCC1954-luc derivative is engineered to stably express firefly luciferase, permitting sensitive, quantitative tracking of tumor burden and metastatic dissemination through non-invasive bioluminescence imaging. When implanted orthotopically into the mammary fat pad of immunodeficient mice such as NSG or SCID strains, HCC1954-luc tumors establish with high engraftment efficiency and faithfully recapitulate the growth kinetics, histopathology, and drug-response profile of human HER2-positive breast cancer, including intrinsic resistance to trastuzumab that mirrors the clinical challenge of primary refractory disease.

Fig 1. Integrin phenotypes and E-cadherin protein expression of HCC-1954 and MCF-7 human breast cancer cell lines. (de Abreu Pereira, Denise, et al., 2022)

The orthotopic placement of HCC1954-luc cells within the mammary fat pad preserves the tumor–stromal crosstalk, extracellular matrix composition, and vasculature architecture essential for modeling HER2-driven angiogenesis and evaluating antibody-based therapeutics that rely on Fc-mediated effector functions. Following primary tumor establishment, surgical resection can be performed to simulate adjuvant treatment paradigms, yielding a postsurgical window during which residual microscopic disease can be monitored via bioluminescence for recurrence and distant metastasis. This model has been extensively leveraged to interrogate next-generation HER2-directed agents—including tyrosine kinase inhibitors, antibody–drug conjugates, bispecific antibodies, and CAR-T cell therapies—making it an indispensable asset for preclinical translation in the HER2-positive breast cancer space.

Cell Line Information: HCC1954-luc

HCC1954-luc is a luciferase-reporter derivative of the parental HCC1954 human breast adenocarcinoma cell line, generated through stable transduction with a firefly luciferase expression cassette driven by a constitutive promoter. The parental line was isolated in 1995 from a primary invasive ductal carcinoma and has since become a reference model for HER2-positive, trastuzumab-resistant breast cancer biology. The luciferase-tagged variant enables quantitative, whole-body optical imaging of tumor dynamics while retaining the parental line's molecular identity and therapeutic response profile. The table below presents the defining characteristics of the HCC1954-luc cell line as applied in orthotopic xenograft construction.

Our Services

Alfa Cytology offers comprehensive HCC1954-luc orthotopic model services spanning cell line expansion and authentication, surgical implantation into the mammary fat pad, serial bioluminescence imaging, tumor resection and postsurgical monitoring, and full-spectrum endpoint characterization including histopathology, immunohistochemistry, and molecular profiling. Our dedicated in vivo oncology team operates under rigorously reviewed IACUC protocols with complete GLP-aligned documentation, ensuring that each study generates reliable, audit-ready data to support your HER2-targeted therapeutic development from lead optimization through IND-enabling evaluation.

Workflow of HCC1954-luc Orthotopic Mouse Model Construction

Establishment of the HCC1954-luc orthotopic breast cancer model follows a carefully orchestrated sequence of cell preparation, surgical implantation, imaging validation, and longitudinal monitoring. The complete workflow typically extends from five to ten weeks depending on study design, with built-in quality assurance measures at each transition point to safeguard data integrity and animal welfare.

1. Cell Line Expansion and Authentication: HCC1954-luc cells are revived from authenticated low-passage cryogenic stocks and expanded in antibiotic-free complete growth medium for a minimum of two passages prior to inoculation. Cell identity is verified by STR profiling against the reference database, and luciferase expression stability is confirmed by in vitro bioluminescence assay using D-luciferin substrate. Mycoplasma screening and viability assessment (>95% by trypan blue exclusion) are performed immediately before harvest.
2. Pre-Implantation Cell Processing: Cells are harvested at sub-confluent density using trypsin-EDTA, washed twice in sterile PBS, and counted by automated hemocytometer. The cell pellet is resuspended in ice-cold PBS or serum-free medium at the target concentration. Where specified by the study protocol, cells are mixed 1:1 with reduced-growth-factor Matrigel to enhance engraftment efficiency in the immunodeficient host environment.
3. Host Preparation and Anesthesia: Female NSG or SCID mice aged 6–10 weeks are quarantined and acclimated for at least seven days under controlled barrier conditions. On the day of surgery, mice are anesthetized with 2–3% isoflurane in medical oxygen delivered via nose cone, with continuous monitoring of respiratory rate and pedal reflex. Body temperature is maintained on a circulating warm-water pad throughout the procedure.
4. Orthotopic Mammary Fat Pad Implantation: The right inguinal mammary fat pad (#4) is exposed through a small paramedian skin incision. Using blunt dissection, the fat pad is gently exteriorized and stabilized with fine forceps. A 27-gauge Hamilton syringe or insulin syringe is used to deliver 25–50 µl of cell suspension (typically 5 × 10⁶ to 1 × 10⁷ cells) into the central stromal region of the fat pad. The needle is held in place for 10 seconds following injection to prevent backflow, after which the fat pad is returned to its anatomical position and the skin is closed with surgical staples or tissue adhesive.
5. Post-Surgical Recovery and Welfare Monitoring: Mice are transferred to a warmed recovery chamber and observed until fully ambulatory and able to self-right. Post-operative analgesia (buprenorphine 0.05–0.1 mg/kg subcutaneously) is administered every 8–12 hours for 48 hours. Body weight, food intake, wound appearance, and activity level are recorded daily for the first week and twice weekly thereafter. Humane endpoint criteria are applied to any animal exhibiting >15% body weight loss, pronounced lethargy, or wound complications.
6. Baseline Bioluminescence Imaging: Between days 3 and 7 post-implantation, mice receive an intraperitoneal injection of D-luciferin (150 mg/kg in 200 µl PBS) and are imaged under maintenance isoflurane anesthesia using an IVIS Spectrum or comparable optical imaging platform. Standardized acquisition parameters (exposure time, binning, f/stop, and field of view) are locked for the duration of the study. Photon flux (photons/second) within a region of interest drawn over the mammary fat pad is quantified to confirm successful engraftment and establish baseline tumor burden.
7. Longitudinal Tumor Growth and Imaging Surveillance: Tumor dimensions are measured twice weekly with digital calipers, and volume is computed as V = (length × width²) / 2. Bioluminescence imaging is repeated at defined intervals (typically every 4–7 days) to track tumor burden non-invasively. Growth curves for both caliper-derived volume and BLI photon flux are generated for individual animals and treatment cohorts, enabling early detection of therapeutic divergence.
8. Primary Tumor Resection (Optional): When tumors reach approximately 400–1,000 mm³ or a predetermined calendar timepoint (typically day 21–35), mice are re-anesthetized and the primary tumor is excised with a 2–3 mm margin of surrounding tissue. Hemostasis is confirmed, the wound is closed in layers, and post-operative care is administered as described above. Tumor resection creates a postsurgical therapeutic window of approximately 4–8 weeks for evaluating adjuvant or anti-metastatic interventions.
9. Postsurgical Recurrence and Metastasis Monitoring: Following resection, mice undergo weekly bioluminescence imaging to detect local tumor recurrence and distant metastatic dissemination. Signal emergence at the surgical bed indicates regrowth, while signal in the thoracic region suggests pulmonary metastasis. Imaging data are correlated with palpation findings and body condition scores to guide endpoint decisions.
10. Necropsy and Endpoint Analysis: At study termination, mice are humanely euthanized and subjected to comprehensive necropsy. Tissues including the residual mammary fat pad, regional lymph nodes, lungs, liver, and bone are harvested for ex vivo bioluminescence confirmation, formalin-fixed paraffin-embedded histopathology (H&E), immunohistochemistry (HER2, Ki-67, cleaved caspase-3), and molecular analyses (Western blot, qPCR, RNA-seq) as dictated by the study objectives.

Fig 2. HCC1954-luc Orthotopic Mouse Model construction workflow.

Case Study-HCC1954-luc Orthotopic Mouse Model Development

In a recent preclinical program, Alfa Cytology deployed the HCC1954-luc orthotopic model to assess the efficacy of a novel HER2-targeting antibody–drug conjugate in combination with a PI3Kα-selective inhibitor. Following orthotopic implantation of 5 × 10⁶ HCC1954-luc cells into NSG mice, tumors were permitted to establish over a 14-day period before randomization into vehicle, monotherapy, and combination treatment arms. Serial bioluminescence imaging revealed that the combination regimen produced a marked and sustained reduction in tumor photon flux compared with either single agent alone, with divergence between groups becoming statistically significant by the third week of dosing. At study endpoint, combination-treated animals exhibited substantially lower final tumor volumes and reduced Ki-67 proliferation indices relative to control cohorts, supporting the mechanistic rationale for dual HER2/PI3K pathway blockade in trastuzumab-resistant HER2-positive disease. These findings illustrate the capacity of the HCC1954-luc orthotopic platform to generate actionable preclinical efficacy and pharmacodynamic data for next-generation combination strategies.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your HCC1954-luc orthotopic study means gaining access to a fully integrated preclinical service infrastructure where cell biology, surgical expertise, advanced imaging, and analytical science converge under one quality-managed roof. We are committed to delivering data packages that withstand the scrutiny of peer review and regulatory review alike.

• Our HCC1954-luc master cell banks are subjected to rigorous STR authentication, mycoplasma clearance, and luciferase expression stability testing to guarantee consistent engraftment and imaging performance across every study cohort.
• We maintain established surgical proficiency in mammary fat pad orthotopic implantation within immunodeficient strains, achieving reproducible tumor take rates with minimal perioperative mortality under fully accredited IACUC oversight.
• On-site IVIS bioluminescence imaging infrastructure allows for rapid turnaround of quantitative tumor burden data, with calibrated ROI analysis and longitudinal photon flux trending reported in publication-grade formats.
• Our flexible study architecture accommodates primary tumor resection schedules, postsurgical adjuvant treatment windows, and multi-arm combination designs tailored to the pharmacological properties of your investigational compounds.
• Integrated endpoint capabilities span histopathology, IHC, digital image analysis, clonogenic assays, and biomarker quantification—eliminating the logistical burden of coordinating multiple external vendors.
• All protocols are executed with comprehensive GLP-aligned documentation, chain-of-custody records, and raw data archival to support IND submissions, investor due diligence, and manuscript preparation.
• Our Ph.D.-level scientific directors bring deep domain knowledge in HER2 signaling, PI3K pathway biology, and antibody pharmacology, and remain actively engaged in study design, interim data interpretation, and report authorship from kickoff to completion.

Contact Us

If your preclinical pipeline demands a validated HER2-positive breast cancer model with quantitative imaging readouts and surgical resection capability, we encourage you to reach out to us to explore how Alfa Cytology can configure an HCC1954-luc orthotopic study around your specific compound, mechanism, and milestone requirements. Contact us now to schedule a consultation with our scientific team and receive a detailed project proposal.

For research use only. Not intended for any clinical use.